RecruitingNCT01731665
Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.
Sponsor
Asan Medical Center
Enrollment
2,000 participants
Start Date
Dec 1, 2012
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to evaluate the incidence, prevalence, clinical characteristics and prognosis of Crohn's disease and ulcerative colitis over time in a district of Seoul, Korea.
Eligibility
Inclusion Criteria12
- Definite cases of CD and UC
- Patients are diagnosed with CD if they meet at least 2 of the following criteria:
- clinical history of abdominal pain, weight loss, malaise, diarrhea, and/or rectal bleeding
- endoscopic findings of mucosal cobblestoning, linear ulceration, skip areas, or perianal disease
- radiologic findings of stricture, fistula, mucosal cobblestoning, or ulceration
- macroscopic appearance of bowel wall induration, mesenteric lymphadenopathy, and "creeping fat" at laparotomy
- pathologic findings of transmural inflammation and/or epithelioid granulomas
- Only patients who meet these criteria for at least 2 months are included.
- Patients are diagnosed with UC only if all 3 of the following criteria are present
- a typical history of diarrhea or blood and pus or both in the stool for longer than 4 weeks
- a typical sigmoidoscopic or colonoscopic picture with diffusely granular, friable, or ulcerated mucosa without rectal sparing or skip lesions or radiological signs of characteristic continuous granular or ulcerated mucosa
- characteristic histopathological signs of inflammation on biopsy
Exclusion Criteria2
- IBD unclassified
- Ethnic groups other than Korean
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01731665
Related Trials
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
NCT060713121 location
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
NCT0658132891 locations
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT0609512849 locations
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
NCT0604575454 locations